Correlation Analyses of Imetelstat Exposure with PharmacodynamicEect, Eicacy and Safety in a Phase 2 Study in Patients withHigher-Risk Myelofibrosis Refractory to Janus Kinase InhibitorIdentified an Optimal Dosing Regimen for Phase 3 Study

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect

RETOUR